Gabapentin Enacarbil
Who holds supplier records for Gabapentin Enacarbil? 4 organisations hold a current record for Gabapentin Enacarbil: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (4).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Gabapentin Enacarbil: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/gabapentin-enacarbil
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 4 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Gabapentin Enacarbil expires 10 Jun 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Gabapentin Enacarbil. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 33296 · latest filing Nov 2018
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 39197 · latest filing Dec 2023
- DASAMI LAB PRIVATE LTDIndia Company GMP cert on recordActive DMF 33386 · latest filing Mar 2019
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 41053 · latest filing Dec 2024
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Gabapentin Enacarbil). The latest listed patent expires 10 Jun 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Gabapentin Enacarbil is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1628502).
Chemical identity
- IUPAC name
- 2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid
- Canonical SMILES
- CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
- InChIKey
- TZDUHAJSIBHXDL-UHFFFAOYSA-N
- Synonyms
- ASP-8825, ASP8825, Gabapentina enacarbilo, Gabapentine enacarbil, Gabapentin enacarbil, Gabapentin encarbil, Gsk-1838262, GSK1838262, Horizant, XP 13512, XP-13512, XP13512
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Physiologic effect
- Decreased Central Nervous System Disorganized Electrical Activity
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Gabapentin Enacarbil?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Gabapentin Enacarbil: ALIVUS LIFE SCIENCES LTD (India), APITORIA PHARMA PRIVATE LTD (India), DASAMI LAB PRIVATE LTD (India) and Zydus Lifesciences Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Gabapentin Enacarbil Drug Master Files are active?
ALIVUS LIFE SCIENCES LTD (DMF 33296), APITORIA PHARMA PRIVATE LTD (DMF 39197), DASAMI LAB PRIVATE LTD (DMF 33386) and Zydus Lifesciences Limited (DMF 41053). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Gabapentin Enacarbil?
Yes. The latest patent listed for an approved US product containing Gabapentin Enacarbil expires 10 Jun 2029, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Gabapentin Enacarbil supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Gabapentin Enacarbil?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.